Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411237 | 1.00 | SLC7A5 (0.38) | SLC7A5AAK1MTNR1AMTNR1BCTSS | |
| SCHEMBL23544353 | 1.00 | SLC7A5 (0.38) | SLC7A5AAK1MTNR1AMTNR1BCTSS | |
| SCHEMBL21029463 | 0.86 | AAK1 (0.43) | SLC7A5AAK1MEN1KMT2A | |
| SCHEMBL10560719 | 0.83 | CTSS (0.49) | SLC7A5AAK1CTSSCTSKNPC1 | |
| SCHEMBL17258287 | 0.82 | ALDH1A1 (0.41) | AAK1ALDH1A1 | |
| SCHEMBL17258288 | 0.82 | ALDH1A1 (0.41) | AAK1ALDH1A1 | |
| SCHEMBL24187349 | 0.81 | DPP4 (0.43) | SLC7A5AAK1MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL31618904 | 0.81 | DPP4 (0.43) | SLC7A5AAK1MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL7340685 | 0.80 | CTSS (0.47) | SLC7A5CTSSCTSKNPC1RAB9A | |
| SCHEMBL10562986 | 0.80 | CTSS (0.47) | SLC7A5CTSSCTSKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132101-A1 | METHOD FOR RESOLVING PHENYLALANINE DERIVATIVE, AND INTERMEDIATE | NEUBORON BIO SCITECH CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| CN-119330846-A | Resolution method and intermediate of phenylalanine derivatives | 中硼（厦门）生物医药有限公司 | 2025-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132101-A1 | METHOD FOR RESOLVING PHENYLALANINE DERIVATIVE, AND INTERMEDIATE | ADH1A, ADH5, NAT1 | SLC7A5 236/4885AAK1 2702/4885MTNR1A 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.